Clene Inc. to Present at H.C. Wainwright 26th Annual Global Investment Conference
TL;DR
Clene (NASDAQ: CLNN) will present at the H.C. Wainwright 26th Annual Global Investment Conference, providing an opportunity for potential investors.
Clene Nanomedicine Inc. is a clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases.
Clene is dedicated to improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases, potentially improving the lives of patients.
CNM-Au8(R) is an investigational first-in-class therapy that targets mitochondrial function, presenting a potential breakthrough in the treatment of neurodegenerative diseases.
Found this article helpful?
Share it with your network and spread the knowledge!
Clene Inc. (NASDAQ: CLNN), along with its wholly-owned subsidiary Clene Nanomedicine Inc., has announced that its management will present at the H.C. Wainwright 26th Annual Global Investment Conference. The event will also feature 1x1 investor meetings. The virtual presentation is set for September 9, 2024, at 7 a.m. EST, and can be accessed via webcast at https://ibn.fm/6ncBJ.
Based in Salt Lake City, Utah, Clene is a clinical-stage biopharmaceutical company dedicated to improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases such as amyotrophic lateral sclerosis (ALS) and multiple sclerosis (MS). The company's innovative approach focuses on enhancing the survival and function of central nervous system cells through its investigational first-in-class therapy, CNM-Au8(R). This treatment targets mitochondrial function and the NAD pathway while reducing oxidative stress.
The announcement of Clene's participation in the prestigious H.C. Wainwright conference underscores the company's ongoing commitment to advancing treatments for debilitating neurodegenerative diseases. Investors and stakeholders will have the opportunity to gain deeper insights into Clene's research and development efforts, as well as its strategic vision for the future.
Neurodegenerative diseases such as ALS and MS represent significant unmet medical needs, affecting millions of people worldwide. Clene's focus on mitochondrial health and neuronal protection could potentially lead to groundbreaking therapies that improve the quality of life for patients suffering from these conditions. The company's participation in the conference may also attract new investment and partnerships, further accelerating the development of its promising therapies.
In addition to its main operations in Utah, Clene also conducts research and manufacturing activities in Maryland. The company's innovative therapies, particularly CNM-Au8(R), are gaining attention for their potential to address complex neurological conditions by improving cell survival and function at a fundamental level.
For more information about Clene and its upcoming presentation, visit the company's newsroom at https://ibn.fm/CLNN.
Curated from InvestorBrandNetwork (IBN)
